Psychedelic People

Dr Max Wolff is a psychedelic researcher from Germany. He's the Head of Psychotherapy Training & Research at the MIND Foundation in Berlin.

Elliot Marseille is a health economist specializing in psychedelics and HIV/AIDS, focusing on cost-effectiveness in global health challenges.

Lotte Merijn is a seasoned coach who has spent several years working in mental health care. Currently, she works as a coach at Flo Coaching.

Chris Koddermann is the Founder & Managing Director of CURA Communications, a communications firm for clients in the psychedelics sector.

Tatayo ("Fruit of the Wind") first arrived in Gabon in 1971 at the age of 21 and became a Gabonese citizen.

Marc Aixala is the author of Psychedelic Integration and is associated with ICEERS, where he is the director of integration and support services.

Genís Ona is a psychologist and pharmacologist and, currently, a PhD candidate in Health, Psychology, and Psychiatry. He is currently conducting scientific research through the International Center for Ethnobotanical Education, Research and Service (ICEERS) and the Medical Anthropology Research Center (MARC; Universitat Rovira i Virgili), mainly studying natural products with psychoactive effects

Willa Hall is the lead researcher on a trial of MDMA-AT for PTSD in healthcare workers.

Felix Müller is a researcher at the University of Basel. He is leading the research project on psychedelics at the Department of Psychiatry.

Ali J. Zarrabi MD is an Assistant Professor at the Department of Family and Preventive Medicine at the Emory University School of Medicine. His work focuses on the physical, emotional, and spiritual care of patients with serious illnesses.

Emmanuelle Schindler is a board-certified Neurologist at Yale School of Medicine in New Haven, with a PhD in Neuroscience. Her research focuses on enhancing the understanding of and improving the lives of patients with cluster headaches.

Director, Translational Research Center, Massachusetts General Hospital; Physician, Lipid Metabolism, Massachusetts General Hospital; Physician Investigator, Lipid Metabolism, Mass General Research Institute; Professor of Medicine, Harvard Medical School.

Diego Pizzagalli is Porfessor of Psychiatry at Harvard Medical School and is an internationally known expert on the neurobiology of depression and has made major contributions toward the identification of biomarkers of depression and treatment response.

Associate Professor in the Child Study Center; Co-Director and Co-Founder of the Pediatric Depression Clinic, Child Study Center; Co-Director of the T32 Postdoctoral Research Fellowship in Childhood Neuropsychiatric Disorders, Child Study Center; Associate Director, Albert J. Solnit Integrated Training Program, Child Study Center; Co-Director of the Tic and OCD Program, Child Study Center

Johan Lundberg currently works at the Department of Clinical Neuroscience, Karolinska Institutet where he is a group leader and associate professor in psychiatry.

Benjamin Kelmendi is a board-certified psychiatrist and is an Assistant Professor in the Department of Psychiatry at the Yale University School of Medicine and is also a co-founder of the Yale Psychedelic Science Group.

Otto Simonsson is a Postdoctoral Research Fellow at the Karolinska Institute where he conducts research on meditation and psychedelics. Otto held a similar position at The Centre for Healthy Minds at the University of Wisconsin-Madison.

Dong-Xin Wang is a Professor and Chairman of the Department of Anesthesiology and Critical Care Medicine at Peking University First Hospital.

José Carlos Bouso is a Clinical Psychologist with a PhD in Pharmacology and is the current Scientific Director at ICEERS.

Declan McLoughlin is a Research Professor of Psychiatry at the Trinity Institute of Neurosciences (TCIN) in Trinity College Dublin.

Rafael dos Santos is a postdoctoral fellow at the Graduate Program in Mental Health at the Faculty of Medicine of Ribeirão Preto (FMRP-USP), where he also works as an accredited advisor.

Anders Fink-Jensen is a Professor of Clinical Psychiatry at the University of Copenhagen.

Deborah Mash is a professor Neurology and Molecular and Cellular Pharmacology at the University of Miami School of Medicine. She is also the Chief Executive Officer and founder of clinical stage pharmaceutical development company DemeRx. Her research is focused on the potential use of ibogaine for opioid and other substance abuse disorders.

Maria Gałuszko-Węgielnik is a psychiatrist associated with the Medical University of Gdansk. Her psychedelic work is currently investigating the effect of ketamine on (treatment-resistant) depression.

Mohini Ranganathan is an Associate Professor of Psychiatry at Yale School of Medicine and is affiliated with Veterans Affairs Connecticut Healthcare System-West Haven.

Franklin Schneier is a Special Lecturer at Columbia University College of Physicians and Surgeons and Research Psychiatrist in the Anxiety Disorders Clinic at New York State Psychiatric Institute.

Dan Iosifescu is an Associate Professor of Psychiatry at NYU School of Medicine and Director of Research at the Nathan S. Kline Institute for Psychiatric Research.

Amelia Adcock is an Associate Professor in the Department of Neurology at West Virginia University.

Joshua Rosenblat is a psychiatrist and clinician-researcher at the Mood Disorders Psychopharmacology Unit at the University of Toronto. He is also the Medical Director of the Canadian Rapid Treatment Centre of Excellence (CRCTE), Chief Medical & Scientific Officer of Braxia Scientific and co-founder of 1907 Research.

Pierre Blier is a Professor at the University of Ottawa, Department of Psychiatry and Cellular/Molecular Medicines and the recipient of the Endowed Chair in Mood Disorders Research at the University of Ottawa Institute of Mental Health Research (IMHR).